Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

This clinical update could positively influence AstraZeneca’s stock performance by bolstering investor confidence in the company’s innovative pipeline. The success of GC012F (AZD0120) could also ...

We will be totally self-sufficient for the supply of medicines to American patients.” AstraZeneca CEO Pascal Soriot on the ...

Intervention/Treatment: The study tests AZD6234, an experimental drug administered through weekly subcutaneous injections. It is designed to work alongside existing GLP-1 RA therapy to improve ...

NHS England has poured investment into hospitals while neglecting other parts of the service, Lord Ara Darzi concluded last year in his report on a “broken system”. The share of the UK health budget ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...